Next 10 |
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in com...
2024-04-09 14:37:37 ET More on Atossa Therapeutics ATOS, SMR and EIGR are among pre market gainers Atossa climbs after cancer therapy update Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Fi...
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The ...
2024-04-05 08:34:13 ET More on premarket gainers & stock NuScale Power Shows Too Many Red Flags NuScale Power: Attractive, Yet High-Risk Nuclear Energy Business NuScale Power Corporation (SMR) Q3 2023 Earnings Call Transcript EIGR, ADXN and BROG are among...
2024-04-01 16:41:34 ET More on Atossa Therapeutics Atossa climbs after cancer therapy update Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeuti...
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 First patient dosed in new Phase 2 breast cancer prevention study Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting Ended 2023 with $88...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
2024-03-19 15:51:38 ET More on Atossa Therapeutics Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therap...
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patien...
2024-03-18 08:40:31 ET More on Atossa Therapeutics Atossa spikes as H.C. Wainwright starts at Buy on lead asset Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics Financial information for Atossa Therap...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in com...
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The ...
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 First patient dosed in new Phase 2 breast cancer prevention study Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting Ended 2023 with $88...